此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)

2026年11月11日 更新者:Aligos Therapeutics

A Phase 1 Trial in Healthy Participants to Evaluate Single and Multiple Oral Dose Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)

A Phase 1 trial of ALG-000184 in healthy participants to assess the safety and tolerability of single and multiple (if applicable) oral doses of ALG-000184 (Part A and B) and ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)

研究概览

研究类型

介入性

注册 (估计的)

55

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Aligos Therapeutics
  • 电话号码:800-466-6059
  • 邮箱:info@aligos.com

学习地点

    • Wisconsin
      • Madison、Wisconsin、美国、53704
        • Aligos Investigational Site
        • 接触:
          • Aligos Investigational Site
          • 电话号码:800-466-6059
          • 邮箱:info@aligos.com

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 60年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria: Key Inclusion Criteria

  1. Parts A and B only: Male or female between 18 and 60 years of age
  2. Part C only: Males between 18 and 55 years of age.
  3. Body mass index between 18.0 kg/m2 and 32.0 kg/m2
  4. In good health, as determined by no clinically significant findings from medical history, 12-lead ECG and vital signs measurements, and clinical laboratory assessments.
  5. Part C only: History of a minimum of 1 bowel movement per day.

Exclusion Criteria: Key Exclusion Criteria:

  1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).

  2. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).

  3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.

  4. Confirmed systolic blood pressure >140 or <90 mmHg, diastolic blood pressure >90 or <50 mmHg, or pulse rate >100 or <40 beats per minute.

  5. Positive hepatitis panel and/or positive human immunodeficiency virus test.

  6. Parts A and B only: Any of the following at screening or check-in:

    1. QTcF >450 ms in males or >470 ms in females
    2. QRS duration >120 ms
    3. PR interval >210 ms
    4. findings which would make QTc measurements difficult or QTc data uninterpretable
  7. Administration of any vaccine within 30 days prior to dosing.

  8. Use or intend to use any prescription medications/products, other than hormone replacement therapy, within 14 days prior to dosing

  9. Alcohol consumption of >21 units per week for males and >14 units per week for females, as applicable.

  10. Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:ALG-000184

Oral tablet(s) of placebo in HV participants once daily for up to 10 days

Single or multiple doses of ALG-000184

安慰剂比较:Placebo

Oral tablet(s) of placebo in HV participants once daily for up to 10 days

Single or multiple doses of Placebo

其他:[14C]ALG-000184

Single oral dose of [14C]ALG-000184

Single micodose of [13C7,15N1]ALG-001075 with combination of [14C]ALG-000184

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety and Tolerability (Part A and B)
大体时间:From enrollment to end of treatment at 10 days

Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
大体时间:From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including AUC0-∞

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
大体时间:From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including AUC0-tlast

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
大体时间:From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including AUC0-τ

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
大体时间:From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including Cmax

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
大体时间:From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including tmax t1/2

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
大体时间:From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including ARAUC

From enrollment to end of treatment at 10 days
Total radioactivity recovery (fet1-t2) in urine and feces (Part C)
大体时间:From enrollment to end of treatment at 10 days

determine the routes, rates of elimination, and mass balance of total radioactivity following a single oral dose of [14C]ALG-000184

From enrollment to end of treatment at 10 days
Metabolic profiles of ALG-000184 (Part C)
大体时间:From enrollment to end of treatment at 10 days

Determine, where possible, the metabolite profiles in plasma, urine, and feces following administration of [14C]ALG-000184

From enrollment to end of treatment at 10 days
Identification of ALG-000184 (Part C)
大体时间:From enrollment to end of treatment at 10 days

Determine, where possible, the chemical structure of major metabolites in plasma, urine, and feces following administration of [14C]ALG-000184

From enrollment to end of treatment at 10 days
Bioavailability of ALG-001075 (Part C)
大体时间:From enrollment to end of treatment at 10 days

Determine the absolute bioavailability of ALG-001075 following oral administration of [14C]ALG-000184 relative to IV administration of [13C7,15N1]ALG-001075

From enrollment to end of treatment at 10 days
PK parameters (Part C)
大体时间:From enrollment to end of treatment at 10 days

PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-∞

From enrollment to end of treatment at 10 days
PK parameters (Part C)
大体时间:From enrollment to end of treatment at 10 days

PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-tlast

From enrollment to end of treatment at 10 days
PK parameters (Part C)
大体时间:From enrollment to end of treatment at 10 days

PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including Cmax

From enrollment to end of treatment at 10 days
PK parameters (Part C)
大体时间:From enrollment to end of treatment at 10 days

PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including tmax

From enrollment to end of treatment at 10 days
PK parameters (Part C)
大体时间:From enrollment to end of treatment at 10 days

PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including t1/2

From enrollment to end of treatment at 10 days

次要结果测量

结果测量
措施说明
大体时间
QTc (Part A and B)
大体时间:From enrollment to end of treatment at 10 days

Evaluate the effect of single and multiple (if applicable) oral doses of ALG-000184 on QTc in healthy participants

From enrollment to end of treatment at 10 days
Safety and Tolerability (Part C)
大体时间:From enrollment to end of treatment at 10 days

Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results

From enrollment to end of treatment at 10 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月14日

初级完成 (估计的)

2027年8月6日

研究完成 (估计的)

2027年10月1日

研究注册日期

首次提交

2026年11月11日

首先提交符合 QC 标准的

2026年11月11日

首次发布 (实际的)

2026年11月17日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • ALG-000184-209

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅